

Aurealis Pharma Expands Its Board of Directors with Mr. Silvio Inderbitzin and Mr. Roger Meier

Basel Switzerland, Kuopio Finland – May 10th 2016.

Aurealis Pharma, a private biopharmaceutical company focused on developing novel multitherapy biologics for chronic inflammation and cancer, today announced the appointment of new board members Mr. Silvio Inderbitzin and Mr. Roger Meier, both from Switzerland. Existing board members CSO and founder Thomas Wirth, CMO and co-founder Dirk Weber and senior life science executive Nora Kaarela were elected to continue as board directors.

“We are pleased to welcome Silvio and Roger to our board. Both of the new directors have a deep breadth of leadership and experience within the life science industry, and very importantly understanding of the stages and challenges of a biopharmaceutical start-up company. Chemistry and mutual understanding on how to develop companies such as Aurealis Pharma is crucial and that was there from day one. We are looking forward to work with them and take our company to the next level” said CEO Juha Yrjänheikki.

“I am very excited about the innovative technology applied by Aurealis Pharma as well as its outstanding team. Thus, it is a great honor for me to be part of the story as investor and member of the board. I will do my best to support the company development, especially in its new Basel location in Switzerland.” stated Dr. Inderbitzin.

“The Aurealis Pharma team has created a unique technology that combines traditionally used lactic acid bacteria with state-of-the-art genetic engineering science. And it is a great example of joining innovative forces in Finland with development resources in Switzerland. I am happy to contribute to the further growth of the company.” continued Mr. Meier.

About Mr. Silvio Inderbitzin

Silvio Inderbitzin has held multiple senior positions in the pharmaceutical industry during the last 20 years. With his origin in pharmaceutical manufacturing, he built a corporate-wide GMP-quality assurance infrastructure as Head of Quality Assurance, and was responsible for product release as a Qualified Person in a medium-sized Swiss pharmaceutical company. He was later elected to the position of Technical Director and served on the Corporate Management Team, ultimately joining the Board of Directors and becoming co-owner of the privately-held 450 employee company. Prior to the successful sale of the company, he served as a CEO and was responsible for its foreign subsidiaries. He



AUREALIS PHARMA

Hochbergerstrasse 60C

CH-4057 Basel

Switzerland

www.aurealispharma.com

Microkatu 1

FI-70210 Kuopio

Finland

is an active investor, consultant and board member of several life science start-up companies. Dr. Inderbitzin studied Pharmacy at the University of Berne, he holds a PhD in Pharmacology from the University of Zurich/ETH, and obtained an Executive MBA from the University of St. Gallen.

About Mr. Roger Meier

Roger Meier is a seasoned early stage life sciences board member and assisted numerous start-up and growth companies and projects in their set-up, talent and fund sourcing. He is the founder and owner of Clarena Ltd., a company that serves corporates and executives in the fields of corporate finance, change management, coaching and HR. In his earlier career, he consulted mid to large sized multinational companies at Coopers & Lybrand (later PwC) in the field of financial and risk management. In the 80's, he helped the US investment bank Salomon Brothers Inc., in the US, UK and Switzerland to establish a Swiss client base with institutional investors. Before he worked as a trader with a Geneva private bank and in Private Banking at Swiss Bank Corp in Basel. In the past years, Roger has been involved in companies like Piquar Therapeutics, Strekin, Cellestia Biotech and many others as advisor and/or co-founder. He holds a finance degree from the University of Applied Sciences in Basel.

Aurealis Pharma is a Basel Switzerland and Kuopio Finland based privately-held biopharmaceutical company focusing on developing broadly applicable proprietary technology to effectively, safely and economically re-educate the distorted host immune microenvironment to proper state. Company's technology is based on safe food-grade lactic acid bacteria delivering multiple human therapeutic proteins in target tissue to address the unmet medical need in chronic wounds and cancer.

For more information:

Juha Yrjänheikki, CEO

Aurealis Pharma

Email: [juha\(at\)aurealispharma.com](mailto:juha(at)aurealispharma.com)

www.aurealispharma.com



AUREALIS PHARMA

Hochbergerstrasse 60C

CH-4057 Basel

Switzerland

www.aurealispharma.com

Microkatu 1

FI-70210 Kuopio

Finland